|
A.S. Ametov (1), E.A. Tertychnaya (2)
Early pathogenetic combined therapy of sugar diabetes type 2: focus on insulin resistance
|
№14 / 2019
|
|
O.D. Ostroumova (1, 2), V.O. Kachan (3), A.I. Kochetkov (1)
Drug-induced hyperthyroidism
|
№14 / 2019
|
|
N.V. Vorokhobina (1), Y.S. Lovkova (2), A.V. Kuznetsova (1), Y.V. Kovalyova (1), N.V. Ivanov (1)
Risk of recurrent thyrotoxicosis and the incidence of obstetric complications in pregnant women with diffuse toxic goiter
|
№14 / 2019
|
|
N.A. Demidov (1), M.A. Balberova (2), M.B. Antsiferov (3)
What can affect the effectiveness of basal insulin therapy for patients with type 2 diabetes mellitus: analysis of the results of real clinical practice according to the diabetes register
|
№14 / 2019
|
|
M.B. Antsiferov (1), N.A. Demidov (2)
Experience in the integrated use of organizational approaches and clinical tools to achieve glycemic control goals
|
№14 / 2019
|
|
N.A. Demidov (1), O.M. Koteshkova (2), M.A. Balberova (3), M.B. Antsiferov (2)
Start of therapy of type 2 diabetes mellitus with a fixed combination. Metformin with vildagliptin or glibenclamide, is there any difference?
|
№14 / 2019
|
|
A.F. Verbovoy, I.A. Tsanava
The importance of adipokines in clinical practice
|
№14 / 2019
|
|
M.V. Leonova
Statins and the risk of diabetes: an evidence-based review
|
№14 / 2019
|
|
A.F. Verbovoy, I.A. Tsanava, N.I Verbovaya., Yu.A. Dolgikh
The polymorbidity and hypothyroidism
|
№14 / 2019
|
|
O.D. Ostroumova (1, 2), I.V. Goloborodova (2)
Hypoglycemic drugs and drug-induced heart failure
|
№14 / 2019
|
|
A.V. Fateeva (1), A.V.Zyuzyukina (2), R.A. Zukov (2)
A clinical case of using ribociclib with an aromatase inhibitor in metastatic hormone-receptor-positive HER2-negative breast cancer with a rare location of metastasis
|
№12 / 2019
|
|
S.V. Khokhlova
Optimal treatment strategy for a patient with advanced ovarian cancer without deterioration in the quality of life: a clinical case
|
№12 / 2019
|
Русский
